| About Jubilant Drug Discovery and Development services (JDDDS) |
Jubilant Drug Discovery and Development Services (JDDDS), is part of the Jubilant LifeSciences family of companies with R&D Centers in India, USA and business offices in Asia, Europe and North America. JDDDS has a global reach and provides comprehensive drug discovery and development solutions from target discovery to clinical development in partnership with leading pharma companies worldwide.
With clear scientific focus in Oncology, Metabolic Disorders, CNS and Pain and Inflammation, JDDDS has rapidly emerged as a leading collaborator for pharma industry. In each of these therapeutic areas, Jubilant has developed a depth of expertise in discovery informatics, medicinal chemistry, structural biology, biology, in vitro, in vivo models and translational sciences. Combined with strong clinical development and manufacturing capabilities, Jubilant has emerged as a fully integrated company with end-to-end solution for pharma industry.
JDDDS business constitutes three Jubilant subsidiaries, Jubilant Biosys (Drug discovery services), Jubilant Chemsys (Chemistry services) and Jubilant Clinsys (Clinical trial services). With over 1200 highly skilled and experienced scientific and medical personnel spread across Bangalore and Noida in India, Europe and the US, the JDDDS vertical leverages the capabilities in emerging markets for a global outcome, accelerating the global drug development efforts. |
|
|
|
| Latest News |
| 20-02-2012 |
| Jubilant and Mnemosyne Pharmaceuticals Announce Drug Discovery Collaboration. |
|
| Jubilant Biosys Limited, Bangalore announced today that they have entered into drug discovery collaboration with Mnemosyne Pharmaceutical Inc, Providence, Rhode Island that will seek to identify preclinical candidates in the area of neuropsychiatric diseases. The collaboration will focus on developing subunit selective NMDA receptor modulators (SNRMs) that Mnemosyne has identified. The alliance shall initially span a period of 2 years and may be extended on mutual consent across other therapeutic programs as well. |
|
|
|
|
|
